bgb-11417
Showing 1 - 7 of 7
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- BGB-11417
- (no location specified)
Jul 18, 2023
Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)
Not yet recruiting
- Mantle Cell Lymphoma
- +2 more
- BGB-11417
- (no location specified)
Jul 25, 2022
Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial (BGB-11417)
Not yet recruiting
- Leukemia
- +4 more
- BGB-11417
- (no location specified)
Jul 27, 2022
Acute Myeloid Leukemia, MDS, Myelodysplastic/Myeloproliferative Tumor Trial in Worldwide (BGB-11417, Azacitidine, Posaconazole)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- BGB-11417
- +2 more
-
Houston, Texas
- +23 more
Aug 18, 2022
Mature B-cell Malignancies Trial in Suzhou (BGB-11417)
Recruiting
- Mature B-cell Malignancies
- BGB-11417
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Suzhou University
Aug 4, 2021
Relapsed/Refractory Multiple Myeloma Trial in Worldwide (BGB-11417, Dexamethasone, Carfilzomib)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- BGB-11417
- +2 more
-
Birmingham, Alabama
- +21 more
Aug 8, 2022
Mature B-Cell Malignancies Trial in Worldwide (BGB-11417, Zanubrutinib)
Recruiting
- Mature B-Cell Malignancies
- BGB-11417
- Zanubrutinib
-
Stanford, California
- +26 more
Dec 16, 2021